Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy

In order to assess the human immunodeficiency virus type 1 (HIV-1) drug resistance mutation profiles and evaluate the distribution of the genetic subtypes in the state of Rio de Janeiro, Brazil, blood samples from 547 HIV-1 infected patients failing antiretroviral (ARV) therapy, were collected during the years 2002 and 2003 to perform the viral resistance genotyping at the Renageno Laboratory from Rio de Janeiro (Oswaldo Cruz Foundation). Viral resistance genotyping was performed using ViroSeqTM Genotyping System (Celera Diagnostic-Abbott, US). The HIV-1 subtyping based on polymerase (pol) gene sequences (protease and reverse transcriptase-RT regions) was as follows: subtype B (91.2%), subtype F (4.9%), and B/F viral recombinant forms (3.3%). The subtype C was identified in two patients (0.4%) and the recombinant CRF_02/AG virus was found infecting one patient (0.2%). The HIV-1 genotyping profile associated to the reverse transcriptase inhibitors has shown a high frequency of the M184V mutation followed by the timidine-associated mutations. The K103N mutation was the most prevalent to the non-nucleoside RT inhibitor and the resistance associated to protease inhibitor showed the minor mutations L63P, L10F/R, and A71V as the more prevalent. A large proportion of subtype B was observed in HIV-1 treated patients from Rio de Janeiro. In addition, we have identified the circulation of drug-resistant HIV-1 subtype C and are presenting the first report of the occurrence of an African recombinant CRF_02/AG virus in Rio de Janeiro, Brazil. A clear association between HIV-1 subtypes and protease resistance mutations was observed in this study. The maintenance of resistance genotyping programs for HIV-1 failing patients is important to the management of ARV therapies and to attempt and monitor the HIV-1 subtype prevalence in Brazil.

HIV and STI surveillance in Northern Ireland 2011: An analysis of data for the calendar year 2010

This annual analysis of data provides an overview of HIV and STI epidemiology in Northern Ireland for the calendar year 2010. Information from a variety of sources is collated and analysed in detail, while any evident trends over time are highlighted�with�graphs and tables. As well as a general summary of STI diagnoses and a number of overall conclusions, the report looks specifically at each of the following STIs: chlamydia, gonorrhoea, genital herpes, genital warts, syphilis, lymphogranuloma venereum (LGV) and HIV.

HIV hasn't gone away

This poster provides a reminder that HIV is still a threat to our health and that to avoid it, we should use a condom for protection. It also provides contact details for the�Genito Urinary Medicine (GUM) clinics in Northern Ireland and the Northern Ireland AIDS Helpline Tel: 0800 137 437.

HIV surveillance in Northern Ireland 2012

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2011.Following recent ONS guidance on data disclosure, where the number of any category of episodes in any one year is between one and four, this is reported either within a cumulative figure, or as an asterix. In addition, where the anonymised figure can be deduced from the totals, the next smallest figure will also be anonymised.

Guidelines for the Management of HIV Positive Pregnant Women in Northern Ireland

This guidance aims to support health care staff to provide the optimum care for HIV positive women during pregnancy and delivery within Northern Ireland.

HIV surveillance in Northern Ireland 2013 : An analysis of data for the calendar year 2012.

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2012.

HIV and STI surveillance in Northern Ireland 2010: An analysis of data for the calendar year 2009

This annual analysis of data provides an overview of HIV and STI epidemiology in Northern Ireland for the calendar year 2009. Information from a variety of sources is collated and analysed in detail, while any evident trends over time are highlighted�with�graphs and tables. As well as a general summary of STI diagnoses and a number of overall conclusions, the report looks specifically at each of the following STIs: chlamydia, gonorrhoea, genital herpes, genital warts, syphilis, lymphogranuloma venereum (LGV) and HIV.

HIV surveillance in Northern Ireland 2014

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2013.

HIV surveillance in Northern Ireland 2015

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2014.

Web per a psicologia i teràpia online Espai Nirvana

Aquest Treball de Final de Carrera engloba l'anàlisi, el disseny i la implementació d'una aplicació web per a psicologia i teràpia online. L'enginyeria d'aquest programari està basada en la tècnica d'orientació a objectes, dins l'estàndard UML. Els aspectes generals de l'anàlisi i disseny s'han desenvolupat amb un cicle de vida en cascada, per tenir una bona base de partida i poder confeccionar una planificació en el temps. La fase de implementació, està basada en un cicle de vida iteratiu e incremental, implementant a cada iteració una petita part amb autonomia que correspon a un cas d'ús. Com a llenguatge de desenvolupament he escollit Java , i com a arquitectura de l'aplicació J2EE, degut a la seva robustesa i a que en l'actualitat, té un fort posicionament en aplicacions web i en xarxa, arribant a ser un estàndard en l'entorn distribuït d'aplicacions empresarials a Internet. En l'estratègia en el disseny i per donar solucions efectives a problemes tipificats, he fet servir el patró MVC, que a més, ha incrementat considerablement la reusabilitat i efectivitat del codi i estructura de la programació. Per a la implementació he incorporat el framework Struts2, que basa la seva arquitectura en el patró MVC, i que ha facilitat molt el treball ja que ha donat solucions a problemes generals estàndard i altres de baix nivell, i ha permès focalitzar els esforços en donar solució a qüestions més particulars i específiques del projecte. En l'accés transparent a les dades he optat per Hibernate3, una poderosa eina que enllaça el món relacional de les BBDD amb el mon de l'orientació a objectes de les classes de les aplicacions. I com a SGBD per a la persistència de dades, he fet servir Oracle 10g XE, també tot un referent en la indústria, i un dels més complets.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.

Background: Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers.   Objective To assess background morbidity as reflected by unsolicited adverse events (AEs), unrelated to study vaccine, reported in clinical trials from four continents. Methods All but three clinical trials were double-blind, randomized, and placebo-controlled. Study procedures and data collection methods were standardized. The frequency and severity of AEs reported during the first year of the trials were analyzed. To avoid confounding by vaccine-related events, solicited reactogenicity and other AEs occurring within 28 d after any vaccination were excluded. Results In total, 2134 AEs were reported by 76% of all participants; 73% of all events were mild. The rate of AEs did not differ between placebo and vaccine recipients. Overall, the percentage of participants with any AE was higher in Africa (83%) compared with Europe (71%), US (74%) and India (65%), while the percentage of participants with AEs of moderate or greater severity was similar in all regions except India. In all regions, the most frequently reported AEs were infectious diseases, followed by gastrointestinal disorders. Conclusions Despite some regional differences, in these healthy participants selected for low risk of HIV infection, background morbidity posed no obstacle to clinical trial conduct and interpretation. Data from controlled clinical trials of preventive interventions can offer valuable insights into the health of the eligible population.